Please assess the completion status of the following clinical trial:

Trial Title: Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* body mass index (BMI) e30 kg/m2 in patients with or without comorbidities, or BMI \>27 kg/m2 in patients with treated or untreated hypertension and/or treated or untreated dyslipidemia.~* stable body weight (variation \<5 kg within 3 months prior to screening visit);~Exclusion Criteria:~* History of very low-calorie diet within 6 months prior to screening visit; or history of surgical procedures for body weight loss (eg, stomach stapling, bypass);~* Presence of any clinically significant psychiatric , neurological or endocrine disease~* Presence of treated or untreated type 1 or type 2 diabetes);~* SBP \>165 mmHg and/or DBP \>105 mmHg on 2 consecutive visits from the screening to the inclusion visit;~* History of myocardial infarction or unstable angina pectoris within 6 months prior to screening visit; and history of stroke within 6 months prior to screening visit;~* Administration of anti-obesity drugs or other drugs for body weight reduction within 3 months prior to screening visit;~The investigator will evaluate whether there are other reasons why a patient may not participate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).